EU Green Lights Apalutamide for Nonmetastatic CRPC
PUBLISHED: 16 NOVEMBER 2018
The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency at its last meeting. The positive opinion will now be reviewed by the European Commission, which approves products for use in the European Union.